OBJECTIVE: To investigate default mode network (DMN) functional connectivity MRI (fcMRI) in a large cross-sectional cohort of subjects from families harboring pathogenic presenilin-1 (PSEN1), presenilin-2 (PSEN2), and amyloid precursor protein (APP) mutations participating in the Dominantly Inherited Alzheimer Network. METHODS: Eighty-three mutation carriers and 37 asymptomatic noncarriers from the same families underwent fMRI during resting state at 8 centers in the United States, United Kingdom, and Australia. Using group-independent component analysis, fcMRI was compared using mutation status and Clinical Dementia Rating to stratify groups, and related to each participant's estimated years from expected symptom onset (eYO). RESULTS: We observed significantly decreased DMN fcMRI in mutation carriers with increasing Clinical Dementia Rating, most evident in the precuneus/posterior cingulate and parietal cortices (p < 0.001). Comparison of asymptomatic mutation carriers with noncarriers demonstrated decreased fcMRI in the precuneus/posterior cingulate (p = 0.014) and right parietal cortex (p = 0.0016). We observed a significant interaction between mutation carrier status and eYO, with decreases in DMN fcMRI observed as mutation carriers approached and surpassed their eYO. CONCLUSION: Functional disruption of the DMN occurs early in the course of autosomal dominant Alzheimer disease, beginning before clinically evident symptoms, and worsening with increased impairment. These findings suggest that DMN fcMRI may prove useful as a biomarker across a wide spectrum of disease, and support the feasibility of DMN fcMRI as a secondary endpoint in upcoming multicenter clinical trials in Alzheimer disease.
OBJECTIVE: To investigate default mode network (DMN) functional connectivity MRI (fcMRI) in a large cross-sectional cohort of subjects from families harboring pathogenic presenilin-1 (PSEN1), presenilin-2 (PSEN2), and amyloid precursor protein (APP) mutations participating in the Dominantly Inherited Alzheimer Network. METHODS: Eighty-three mutation carriers and 37 asymptomatic noncarriers from the same families underwent fMRI during resting state at 8 centers in the United States, United Kingdom, and Australia. Using group-independent component analysis, fcMRI was compared using mutation status and Clinical Dementia Rating to stratify groups, and related to each participant's estimated years from expected symptom onset (eYO). RESULTS: We observed significantly decreased DMN fcMRI in mutation carriers with increasing Clinical Dementia Rating, most evident in the precuneus/posterior cingulate and parietal cortices (p < 0.001). Comparison of asymptomatic mutation carriers with noncarriers demonstrated decreased fcMRI in the precuneus/posterior cingulate (p = 0.014) and right parietal cortex (p = 0.0016). We observed a significant interaction between mutation carrier status and eYO, with decreases in DMN fcMRI observed as mutation carriers approached and surpassed their eYO. CONCLUSION: Functional disruption of the DMN occurs early in the course of autosomal dominant Alzheimer disease, beginning before clinically evident symptoms, and worsening with increased impairment. These findings suggest that DMN fcMRI may prove useful as a biomarker across a wide spectrum of disease, and support the feasibility of DMN fcMRI as a secondary endpoint in upcoming multicenter clinical trials in Alzheimer disease.
Authors: Serge Gauthier; Barry Reisberg; Michael Zaudig; Ronald C Petersen; Karen Ritchie; Karl Broich; Sylvie Belleville; Henry Brodaty; David Bennett; Howard Chertkow; Jeffrey L Cummings; Mony de Leon; Howard Feldman; Mary Ganguli; Harald Hampel; Philip Scheltens; Mary C Tierney; Peter Whitehouse; Bengt Winblad Journal: Lancet Date: 2006-04-15 Impact factor: 79.321
Authors: Michael D Fox; Abraham Z Snyder; Justin L Vincent; Maurizio Corbetta; David C Van Essen; Marcus E Raichle Journal: Proc Natl Acad Sci U S A Date: 2005-06-23 Impact factor: 11.205
Authors: Eric M Reiman; Yakeel T Quiroz; Adam S Fleisher; Kewei Chen; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Anne M Fagan; Aarti R Shah; Sergio Alvarez; Andrés Arbelaez; Margarita Giraldo; Natalia Acosta-Baena; Reisa A Sperling; Brad Dickerson; Chantal E Stern; Victoria Tirado; Claudia Munoz; Rebecca A Reiman; Matthew J Huentelman; Gene E Alexander; Jessica B S Langbaum; Kenneth S Kosik; Pierre N Tariot; Francisco Lopera Journal: Lancet Neurol Date: 2012-11-06 Impact factor: 44.182
Authors: Erik Barry Erhardt; Srinivas Rachakonda; Edward J Bedrick; Elena A Allen; Tülay Adali; Vince D Calhoun Journal: Hum Brain Mapp Date: 2010-12-15 Impact factor: 5.038
Authors: Eric McDade; Guoqiao Wang; Brian A Gordon; Jason Hassenstab; Tammie L S Benzinger; Virginia Buckles; Anne M Fagan; David M Holtzman; Nigel J Cairns; Alison M Goate; Daniel S Marcus; John C Morris; Katrina Paumier; Chengjie Xiong; Ricardo Allegri; Sarah B Berman; William Klunk; James Noble; John Ringman; Bernardino Ghetti; Martin Farlow; Reisa A Sperling; Jasmeer Chhatwal; Stephen Salloway; Neill R Graff-Radford; Peter R Schofield; Colin Masters; Martin N Rossor; Nick C Fox; Johannes Levin; Mathias Jucker; Randall J Bateman Journal: Neurology Date: 2018-09-14 Impact factor: 9.910
Authors: Yakeel T Quiroz; Aaron P Schultz; Kewei Chen; Hillary D Protas; Michael Brickhouse; Adam S Fleisher; Jessica B Langbaum; Pradeep Thiyyagura; Anne M Fagan; Aarti R Shah; Martha Muniz; Joseph F Arboleda-Velasquez; Claudia Munoz; Gloria Garcia; Natalia Acosta-Baena; Margarita Giraldo; Victoria Tirado; Dora L Ramírez; Pierre N Tariot; Bradford C Dickerson; Reisa A Sperling; Francisco Lopera; Eric M Reiman Journal: JAMA Neurol Date: 2015-08 Impact factor: 18.302
Authors: Miles Berger; Deborah Oyeyemi; Mobolaji O Olurinde; Heather E Whitson; Kent J Weinhold; Marty G Woldorff; Lewis A Lipsitz; Eugene Moretti; Charles M Giattino; Kenneth C Roberts; Junhong Zhou; Thomas Bunning; Michael Ferrandino; Randall P Scheri; Mary Cooter; Cliburn Chan; Roberto Cabeza; Jeffrey N Browndyke; David M Murdoch; Michael J Devinney; Leslie M Shaw; Harvey Jay Cohen; Joseph P Mathew Journal: J Am Geriatr Soc Date: 2019-01-23 Impact factor: 5.562
Authors: Aaron P Schultz; Jasmeer P Chhatwal; Trey Hedden; Elizabeth C Mormino; Bernard J Hanseeuw; Jorge Sepulcre; Willem Huijbers; Molly LaPoint; Rachel F Buckley; Keith A Johnson; Reisa A Sperling Journal: J Neurosci Date: 2017-03-17 Impact factor: 6.167
Authors: Li Juan Zheng; Yun Yan Su; Yun Fei Wang; U Joseph Schoepf; Akos Varga-Szemes; Jonathan Pannell; Xue Liang; Gang Zheng; Guang Ming Lu; Gui Fen Yang; Long Jiang Zhang Journal: Mol Neurobiol Date: 2017-05-13 Impact factor: 5.590
Authors: Jewell B Thomas; Matthew R Brier; Randall J Bateman; Abraham Z Snyder; Tammie L Benzinger; Chengjie Xiong; Marcus Raichle; David M Holtzman; Reisa A Sperling; Richard Mayeux; Bernardino Ghetti; John M Ringman; Stephen Salloway; Eric McDade; Martin N Rossor; Sebastien Ourselin; Peter R Schofield; Colin L Masters; Ralph N Martins; Michael W Weiner; Paul M Thompson; Nick C Fox; Robert A Koeppe; Clifford R Jack; Chester A Mathis; Angela Oliver; Tyler M Blazey; Krista Moulder; Virginia Buckles; Russ Hornbeck; Jasmeer Chhatwal; Aaron P Schultz; Alison M Goate; Anne M Fagan; Nigel J Cairns; Daniel S Marcus; John C Morris; Beau M Ances Journal: JAMA Neurol Date: 2014-09 Impact factor: 18.302